2024 Virtual Grand Rounds
2024 Virtual Grand Rounds Session 14: November 6, 2024 - Highlights from Fall Clinical 2024: Your Questions Answered
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, November 6, 2024
8 PM ET / 5 PM PT
Highlights from Fall Clinical 2024: Your Questions Answered
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
November 7, 2024
November 7, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss the pathogenesis and optimal management of psoriasis, atopic dermatitis and acne vulgaris
Update knowledge regarding recent advances in the safe and effective use of biologic agents for the treatment of dermatologic diseases
Enhance the ability to evaluate and incorporate new techniques and uses of dermal fillers and neurotoxins
Identify and describe the indications, contraindications, and evidence-based safety and efficacy profiles of new agents approved for use in the dermatology setting Integrate prevention, diagnosis, and management of skin cancer into my clinical setting
Diagnose commonly presented dermatologic disorders
Improve my clinical interactions with patients
Integrate knowledge to enhance daily dermatologic care
Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Andrew Alexis, MD, MPH
Vice-Chair for Diversity and Inclusion, Dept. of Dermatology
Professor of Clinical Dermatology
Weill Cornell Medicine
New York, NY
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Alexandra Golant, MD
Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Mark Nestor, MD, PhD
Director of Center for Clinical and Cosmetic Research
Voluntary Professor, Dermatology
University of Miami, Miller School of Medicine
Miami, FL
Darrell Rigel, MS, MD
Clinical Professor of Dermatology
New York University
Grossman School of Medicine
New York, NY
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: BMS, LEO, Novartis, Almirall
Consultant: Leo, Galderma, Pfizer, Sanofi- Regeneron
Speakers’ Bureau or Honoraria: Regeneron, SANOFI-Genzyme, Pfizer, BMS
Advisory Board/Consultant: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer
Grant/Research Support: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer
Advisory Board: Abbvie, Amgen, Arcutis, BMS, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Pfizer, Regeneron, Sanofi
Consultant: Abbvie, Arcutis, Dermavant, Galderma, Lilly, Regeneron, Sanofi
Speakers’ Bureau Honoraria: Abbvie, Arcutis, Dermavant, Galderma, Incyte, Lilly, Pfizer, Regeneron, Sanofi
Grant/Research Support: Abbvie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio Biosciences, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB, Inc.
Consultant: Almirall, AltruBio Inc., AnaptysBio, Apogee Therapeutics, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, EPI, Evommune, Inc., Facilitation of International Dermatology Education, Forte biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda,Trevi, and Verrica
Advisory Board: Algeness, AMP Biologics, Castle Biosciences, Eirion Therapeutics Inc., Ferndale, Galderma, HTL Research, Hugel America, Ipsen, Novaestiq Corp, Primus Pharmaceuticals, RVL Pharmaceuticals, Sensus Healthcare, Sirnaomics
Grant/Research Support: Castle Biosciences, CROMA Pharma GmbH, Dermata Therapeutics, Eirion Therapeutics Inc., Fudan-Zhangjiang Co. Ltd., Galderma, Incyte corp., Jetema Co., Krystal Biotech, Mediwound, Merz Pharma, Mino Labs, Sirnaomics, Suneval Medical, Sun Pharma, Veradermics Inc.
Consultant: Aerolase, AMP Biologics, Benev Co. Inc., CROMA Pharma GmbH, Dermsquared, Eirion Therapeutics Inc., Emblation / Sarosa, HTL Research, Ipsen, Mediwound, Novaestiq Corp, Primus Pharmaceuticals, Revian, Sensus Healthcare, Sirnaomics, Sofwave, Vial
Speakers/ Bureau or Honoraria: Sensus Healthcare
Advisory Board: Castle Biosciences, Almirall
Grant/Research Support: Castle Biosciences
Consultant: Castle Biosciences
Speakers’ Bureau Honoraria: Beiersdorf, Castle Biosciences, Almirall, DermTech
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.